logo
Plus   Neg
Share
Email

Rio Tinto H1 Net Profit Declines; Announces $3.5 Bln Interim Returns

Rio Tinto plc (TPPF.PK,RIO.L,RIO,RTNTF.PK) reported first-half net earnings of $4.1 billion, down 6% from prior year, due to the impairment of Oyu Tolgoi. Earnings per share in cents was 250.7 compared to 249.9. Underlying EBITDA was $10.3 billion, up 19% from prior year, excluding the $0.6 billion contribution from coking coal. The increase reflected higher iron ore prices, the company said. Basic underlying earnings per share in cents was 301.5 compared to 253.6.

First-half consolidated sales revenue was $20.7 billion, an increase of 9% from prior year, excluding the $0.8 billion contribution from the coking coal assets divested in 2018.

The company's 2019 production guidance is unchanged from its second quarter operations review.

Rio Tinto also announced returns to shareholders of $3.5 billion including interim
dividend of $2.5 billion and special dividend of $1.0 billion. The 2019 interim dividend, equivalent to 151 US cents per share, and the special dividend, equivalent to 61 US cents per share, will be paid on 19 September 2019 to shareholders on the register at the close of business on 9 August 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. is introducing a new protein to its menu, Carne Asada, starting this week. Carne Asada is Chipotle's newest protein addition since it reintroduced chorizo in September 2018. The Mexican food chain said that the new steak option will be available at its restaurants nationwide from Thursday, September 19, 2019. Pizza Hut has partnered with Cheez-It to launch a new item to its menu - the Stuffed Cheez-It Pizza. The pizza chain, a subsidiary of Yum! Brands, said that the new item combines Pizza Hut pizza and the Cheez-It cheese snack. Stuffed Cheez-It Pizza will be available on Pizza Hut menus nationwide for a limited-time. Pizza Hut is the official pizza sponsor of the NFL and NCAA. The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world.
Follow RTT